Although anti-PD-1/PDL-1 antibodies have been found to cause cardiotoxicity, a case series reported that anti-PDL-1 inhibitors (atezolizumab, durvalumab, avelumab) result in less immune-mediated myocarditis than anti-PD-1 drugs (Table 2). Here, PDCD1 is linked to myocarditis.